Drug intelligence / Profile preview

Liothyronine (University of Minnesota)

Development stage: Approved
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Liothyronine is a synthetic form of the thyroid hormone triiodothyronine (T3). It is primarily used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. It also helps decrease the size of an enlarged thyroid gland (goiter) and can be used in the treatment of thyroid cancer. Liothyronine works by binding to specific nuclear receptor sites, influencing gene transcription and protein synthesis, thereby increasing the basal metabolic rate and affecting protein synthesis. It is considered the most potent form of thyroid hormone.

Brand names: CytomelTertroxin
Other names: Triiodothyronine

Targets

THRA (Thyroid hormone receptor alpha)PVRTHRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on Liothyronine (University of Minnesota).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liothyronine (University of Minnesota).

Explore the full profile